Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
CORKA logo

The CORKA study is a trial looking at a functional home based rehabilitation programme for patients who may be at risk of poor outcome after knee replacement. Participants were randomised to one of two arms, ‘home-based rehabilitation’ or ‘Usual Care’. Those in the usual care arm received a minimum of 1 and a maximum of 6 sessions of physiotherapy as delivered locally, e.g. class, one to one, etc. Those in the intervention arm received 7 sessions of a functional rehabilitation programme over a 12 week timescale. The intervention will be delivered using physiotherapists and physiotherapy assistants in the participants’ home. Participants will be followed up at 6 months and 12 months.

The Primary outcome is to compare the patient reported functional outcome and quality of life of the CORKA trial rehabilitation protocol versus standard care in participants at risk of poor outcome after knee replacement.

On 22nd January 2018 CORKA reached its target of 620 participants, recruited at 14 Hospitals in England. The CORKA study is funded by the HTA Programme. Follow up will finish in December 2018 and the results will be disseminated in December 2019.

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

ARCADIAN trial opens to recruitment!

OCTRU

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.